Market Overview:
The global Zika virus vaccines market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of Zika virus infections, rising awareness about Zika virus vaccines, and technological advancements in vaccine development. However, the high cost of commercialized Zika virus vaccines may restrain the growth of this market to some extent. The global Zika virus vaccines market is segmented on the basis of type, application, and region. On the basis of type, it is divided into DNA vaccine, inactivated vaccine, purified inactivated vaccine (PIV), and others (recombinant subunit protein & live attenuated). The DNA vaccine segment is expected to grow at a higher CAGR during the forecast period as compared to other segments owing to its advantages such as high efficacy and safety profile. On the basis of application, it is classified into hospitals & clinics; academic & research institutions; government organizations; manufacturers/distributors/suppliers; and others (travelers). Hospitals & clinics are anticipated witness highest demand for Zika virus vaccines due to increasing number outbreaks reported across different parts world.
Product Definition:
Zika virus vaccines are a class of vaccine that protect against infection by the Zika virus. As of 2017, there are no licensed Zika virus vaccines available. However, several vaccine candidates are in development.
DNA Vaccine:
DNA vaccines are a new type of vaccine that uses DNA as a carrier to deliver the contents of the vaccine into the body. The first attempt at creating such a vaccine was made in 1980, by Watson and Crick, who discovered the structure of DNA. Since then many research groups have been working on this technology to create safe and effective vaccines for various diseases such as HIV, Ebola virus disease (EVD), H1N1 influenza virus among others.
Inactivated Vaccine:
Inactivated or killed vaccines are usually made from the whole virus and they do not cause disease. They are used as vaccine carriers to help the body's immune system recognize and respond to the real virus. In this way, it helps protect against diseases like measles, polio, chickenpox, mumps, rubella (MMR), hepatitis A & B (HAV & HBV), influenza (flu), zoster (shingles), etc.
Application Insights:
Based on application, the market is segmented into hospitals, clinics, academic and research institutes, and others. Hospitals are considered to be the largest users of vaccines as they have a high volume of patients that need to be protected against various diseases. The use of these products in hospitals has increased significantly due to their ability to protect people from severe infections for a longer period of time.
The use of these vaccines in clinics is expectedto increase at a significant rate over the forecast period owing toraeroprotein expression levels after infection by Zika virus among other indications that allow clinicians toraeroprotein expression levels after infection by Zika virus among other indications that allow clinicians rapid diagnosis during active follow-up or early disease detection.
Regional Analysis:
North America dominated the market in 2017 owing to factors such as the presence of a large number of manufacturers, suppliers, and researchers; high disposable income; and well-established healthcare infrastructure. The region is expected to maintain its dominance over the forecast period due to continuous R&D activities for development of new vaccines. In addition, increasing cases of dengue fever have led governments across countries such as Brazil and Mexico to focus on developing a vaccine against Zika virus. This has resulted in an increased demand for these vaccines in North America.
Asia Pacific is anticipated to be one of the fastest growing regions during the forecast period owing with rapid economic growth especially in countries like India, China, Indonesia & Thailand which are experiencing rising population along with increasing incidence rates associated with mosquito-borne illnesses including dengue fever & Zika virus infection areas).
Growth Factors:
- Increasing incidence of Zika virus infections: The incidence of Zika virus infections is increasing rapidly across the globe. This is expected to drive the demand for Zika virus vaccines in the near future.
- Government initiatives for vaccine development: Several governments are taking initiatives to develop vaccines for Zika virus infection. This is likely to boost the growth of the market in coming years.
- Growing awareness about Zika virus: There is a growing awareness about Zika virus and its associated risks among people across the world. This is likely to create a positive impact on the growth of this market in future years.
- Technological advancements in vaccine development: The technological advancements in vaccine development are aiding faster and better production of effective vaccines against various diseases, including Zika Virus Vaccines market .
Scope Of The Report
Report Attributes
Report Details
Report Title
Zika Virus Vaccines Market Research Report
By Type
DNA Vaccine, Inactivated Vaccine, Purified Inactivated Vaccine, Table of Contents
By Application
Hospitals, Clinics, Academic and Research, Others
By Companies
NHI, Sanofi, GSK, Bharat., Takeda, Inovio Pharmaceuticals, GeneOne Life Science Inc, PaxVax, Gilead Sciences Inc., Intrexon Corp., NewLink Genetics Corp
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Zika Virus Vaccines Market Report Segments:
The global Zika Virus Vaccines market is segmented on the basis of:
Types
DNA Vaccine, Inactivated Vaccine, Purified Inactivated Vaccine, Table of Contents
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Academic and Research, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- NHI
- Sanofi
- GSK
- Bharat.
- Takeda
- Inovio Pharmaceuticals
- GeneOne Life Science Inc
- PaxVax
- Gilead Sciences Inc.
- Intrexon Corp.
- NewLink Genetics Corp
Highlights of The Zika Virus Vaccines Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- DNA Vaccine
- Inactivated Vaccine
- Purified Inactivated Vaccine
- Table of Contents
- By Application:
- Hospitals
- Clinics
- Academic and Research
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Zika Virus Vaccines Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Zika virus vaccines are a type of vaccine that help protect people from getting Zika virus. There is currently no cure or prevention for Zika, but vaccines can help protect people from getting sick with the virus.
Some of the major companies in the zika virus vaccines market are NHI, Sanofi, GSK, Bharat., Takeda, Inovio Pharmaceuticals, GeneOne Life Science Inc, PaxVax, Gilead Sciences Inc., Intrexon Corp., NewLink Genetics Corp.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Zika Virus Vaccines Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Zika Virus Vaccines Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Zika Virus Vaccines Market - Supply Chain
4.5. Global Zika Virus Vaccines Market Forecast
4.5.1. Zika Virus Vaccines Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Zika Virus Vaccines Market Size (000 Units) and Y-o-Y Growth
4.5.3. Zika Virus Vaccines Market Absolute $ Opportunity
5. Global Zika Virus Vaccines Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Zika Virus Vaccines Market Size and Volume Forecast by Type
5.3.1. DNA Vaccine
5.3.2. Inactivated Vaccine
5.3.3. Purified Inactivated Vaccine
5.3.4. Table of Contents
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Zika Virus Vaccines Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Zika Virus Vaccines Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Academic and Research
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Zika Virus Vaccines Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Zika Virus Vaccines Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Zika Virus Vaccines Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Zika Virus Vaccines Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Zika Virus Vaccines Demand Share Forecast, 2019-2026
9. North America Zika Virus Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Zika Virus Vaccines Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Zika Virus Vaccines Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Academic and Research
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Zika Virus Vaccines Market Size and Volume Forecast by Type
9.7.1. DNA Vaccine
9.7.2. Inactivated Vaccine
9.7.3. Purified Inactivated Vaccine
9.7.4. Table of Contents
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Zika Virus Vaccines Demand Share Forecast, 2019-2026
10. Latin America Zika Virus Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Zika Virus Vaccines Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Zika Virus Vaccines Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Academic and Research
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Zika Virus Vaccines Market Size and Volume Forecast by Type
10.7.1. DNA Vaccine
10.7.2. Inactivated Vaccine
10.7.3. Purified Inactivated Vaccine
10.7.4. Table of Contents
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Zika Virus Vaccines Demand Share Forecast, 2019-2026
11. Europe Zika Virus Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Zika Virus Vaccines Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Zika Virus Vaccines Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Academic and Research
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Zika Virus Vaccines Market Size and Volume Forecast by Type
11.7.1. DNA Vaccine
11.7.2. Inactivated Vaccine
11.7.3. Purified Inactivated Vaccine
11.7.4. Table of Contents
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Zika Virus Vaccines Demand Share, 2019-2026
12. Asia Pacific Zika Virus Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Zika Virus Vaccines Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Zika Virus Vaccines Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Academic and Research
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Zika Virus Vaccines Market Size and Volume Forecast by Type
12.7.1. DNA Vaccine
12.7.2. Inactivated Vaccine
12.7.3. Purified Inactivated Vaccine
12.7.4. Table of Contents
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Zika Virus Vaccines Demand Share, 2019-2026
13. Middle East & Africa Zika Virus Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Zika Virus Vaccines Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Zika Virus Vaccines Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Academic and Research
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Zika Virus Vaccines Market Size and Volume Forecast by Type
13.7.1. DNA Vaccine
13.7.2. Inactivated Vaccine
13.7.3. Purified Inactivated Vaccine
13.7.4. Table of Contents
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Zika Virus Vaccines Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Zika Virus Vaccines Market: Market Share Analysis
14.2. Zika Virus Vaccines Distributors and Customers
14.3. Zika Virus Vaccines Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. NHI
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GSK
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bharat.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Takeda
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Inovio Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GeneOne Life Science Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. PaxVax
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Gilead Sciences Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Intrexon Corp.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. NewLink Genetics Corp
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook